As an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, gefitinib is widely used as targeted therapy of NSCLC patients, which significantly improves the overall survival rate of lung cancer62. Here, EGFR is linked to non-small cell lung carcinoma.